Regulation FD Disclosure

SEC Form 8-K Summary

Registrant: Bull Horn Holdings Corp. (metadata identifies Z Squared Inc.; the filing itself names Bull Horn Holdings Corp.)

Reporting date: July 6, 2022. This is a current report under Item 7.01, Regulation FD, concerning a proposed business combination.

Business Context and Transaction

Bull Horn, a British Virgin Islands special purpose acquisition company, furnished an investor presentation regarding its proposed merger with Coeptis Therapeutics, Inc. under an April 18, 2022 Merger Agreement. BH Merger Sub Inc., a wholly owned subsidiary of Bull Horn, is also a party to the agreement.

The transaction remains subject to shareholder approval and other closing conditions. Bull Horn had filed a Form S-4 containing a preliminary proxy statement/prospectus; definitive transaction materials were to be provided when available.

Financial Metrics and Liquidity

The filing does not provide clear revenue, profit, cash flow, margin, debt, liquidity, valuation, or other operating-financial metrics. The filing is primarily a transaction communication and furnishes an investor presentation rather than financial statements.

Material Changes Versus Prior Period

No comparable-period financial information or material operating changes are reported. The material development is the furnishing of the July 2022 investor presentation related to the proposed Bull Horn-Coeptis transaction.

Outlook, Risks, and Contingencies

  • Completion timing and anticipated financial effects of the transaction are forward-looking and uncertain.
  • The Merger Agreement could be terminated, and the transaction may not close if shareholder approval or other conditions are not satisfied.
  • Significant redemptions by Bull Horn public shareholders could leave the combined company with limited funds to execute its business plans.
  • Continued Nasdaq listing following the transaction may not be obtained or maintained.
  • Coeptis products in development may fail clinical trials or may not receive FDA or other regulatory approval.
  • Other risks include transaction costs, changes in law or regulation, competition, growth-management challenges, employee retention, operational disruption, and COVID-19-related effects.
  • The presentation is furnished, not filed for purposes of Exchange Act Section 18 liability, and is not incorporated by reference except where specifically stated.

Key Facts for Investors to Verify

  • Review the preliminary and definitive proxy statement/prospectus and subsequent SEC filings for transaction terms, closing conditions, dilution, and redemption mechanics.
  • Verify whether Bull Horn shareholders approve the transaction and whether all other closing conditions are satisfied.
  • Assess the amount of cash available after redemptions and transaction expenses.
  • Review Coeptis’s clinical, regulatory, commercialization, and financing risks.
  • Confirm the combined company’s intended Nasdaq listing and post-closing capital structure.

Exhibit

Exhibit 99.1: Investor Presentation, dated July 2022. Exhibit 104: Inline XBRL cover page data.

Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.